https://caltcm.memberclicks.net/assets/documents/acc_aha_chf_2013_guidelines.pdf

2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications

![Figure][1] 





![Figure][1] 





![Figure][1] 





![Figure][1] 





![Figure][1] 





![Figure][1] 





![Figure][1] 





![Figure][1] 





![Figure][1] 





![Figure][1] 





![Figure][1] 





![Figure][1] 





![Figure][1

/pdf/acc-aha-2005-guideline-update-for-the-diagnosis-and-4hik65ngbe.pdf

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult

ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure).

Mariell Jessup, MD, FACC, FAHA, Chair [*][1]

William T. Abraham, MD, FACC, FAHA[†][2]

Donald E. Casey, MD, MPH, MBA[‡][3]

Arthur M. Feldman, MD, PhD, FACC, FAHA[§][4]

Gary S. Francis, MD, FACC, FAHA[§][4]

Theodore G. Ganiats, MD[∥][5]

Marvin A. Konstam, MD, FACC[¶][6]

Donna M.

/pdf/2009-focused-update-incorporated-into-the-acc-aha-2005-3z9lhvyqwq.pdf

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation

Pharmacokinetics, Second Edition

Noncompartmental Analysis Based on Statistical Moment Theory

Noncompartmental Determination of the Steady-State Volume of Distribution for Any Mode of Administration

Several recent reports have shown that plasma concentrations of digoxin increase when quinidine is administered along with digoxin; the present study was designed to explore the pharmacokinetics of this digoxin-quinidine interaction in six subjects. The elimination half-life of digoxin, although variable, did not change appreciably (42 vs. 44 hours) when quinidine was administered. Other pharmacokinetic values were substantially reduced in the presence of quinidine: total body clearance (from 3.08 to 1.96 ml per minute per kilogram), renal clearance (from 1.64 to 1.09 ml per minute per kilogram) and volume of distribution (from 10.87 to 7.35 liters per kilogram). The results may be explained by the displacement of digoxin from binding sites in tissue by quinidine, causing a rise in the plasma concentration of digoxin. The reduction in renal clearance of digoxin may result also from inhibition of renal secretion of digoxin by quinidine.

Digoxin-quinidine interaction Pharmacokinetic evaluation.

Clearance and half-life are evaluated as indices of the intrinsic capacity of the liver to metabolize drugs. The utility of these parameters as indices of hepatic elimination is highly dependent upon the pharmacokinetic characteristics of a particular drug. For drugs which confer the pharmacokinetic characteristics of a single compartment model on the body, both half-life and clearance serve as meaningful measures of hepatic elimination. However, for a drug which confers multicompartment characteristics on the body, biologic half-life does not reflect properly the intrinsic metabolic activity of the liver. Clearance, on the other hand, is a direct measure of this activity regardless of the number of compartments conferred upon the body by a drug provided the liver is an integral part of the central compartment. For drugs subject to first-pass metabolism, the applicability of clearance as an index of hepatic metabolism is considerably more limited. After the intravenous administration of a drug, which is subject to first-pass metabolism on oral administration, the reliability of body clearance as an index of hepatic elimination becomes less meaningful as the potential for first-pass metabolism increases. After oral administration, however, body clearance appears to reflect directly intrinsic metabolic activity regardless of the extent of first-pass metabolism.

Donald Perrier

Papers

Pharmacokinetics, Second Edition

Noncompartmental Analysis Based on Statistical Moment Theory

Noncompartmental Determination of the Steady-State Volume of Distribution for Any Mode of Administration

Digoxin-quinidine interaction Pharmacokinetic evaluation.

Clearance and biologic half-life as indices of intrinsic hepatic metabolism.